Matches in Nanopublications for { ?s ?p "[Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_assertion description "[Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666141.RA2UMJhfaQ3jtB6bFtZbL9i5TP4Jj4KBNM-5bM9qIo7wg130_provenance.
- NP326118.RAQFhqFZiFqG1_O5Ob9MyWcxxXfy1UW0h62cT3g7ER3WE130_assertion description "[Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326118.RAQFhqFZiFqG1_O5Ob9MyWcxxXfy1UW0h62cT3g7ER3WE130_provenance.
- NP326084.RAn_7v2wNxTueBKcg1ulSe8ALTCJk1fGmx9m0GldEUquU130_assertion description "[Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326084.RAn_7v2wNxTueBKcg1ulSe8ALTCJk1fGmx9m0GldEUquU130_provenance.
- NP622786.RAPkAGkzHbSp5jePMiV0_EJt01zLOVutOxeD_SaPKwmCc130_assertion description "[Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622786.RAPkAGkzHbSp5jePMiV0_EJt01zLOVutOxeD_SaPKwmCc130_provenance.
- NP622784.RA1UJXtTEyt3ZM7I2KP4ptv4Bg0Y5MVX3OqaG1lv1g8sM130_assertion description "[Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622784.RA1UJXtTEyt3ZM7I2KP4ptv4Bg0Y5MVX3OqaG1lv1g8sM130_provenance.